-$1.25 EPS Expected for Reata Pharmaceuticals Inc (NASDAQ:RETA) This Quarter

Share on StockTwits

Brokerages expect Reata Pharmaceuticals Inc (NASDAQ:RETA) to report earnings of ($1.25) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Reata Pharmaceuticals’ earnings, with estimates ranging from ($1.28) to ($1.17). Reata Pharmaceuticals reported earnings per share of ($1.07) during the same quarter last year, which would indicate a negative year over year growth rate of 16.8%. The firm is expected to issue its next earnings results on Wednesday, November 6th.

On average, analysts expect that Reata Pharmaceuticals will report full year earnings of ($5.33) per share for the current fiscal year, with EPS estimates ranging from ($7.31) to ($4.60). For the next fiscal year, analysts anticipate that the business will report earnings of ($6.87) per share, with EPS estimates ranging from ($11.67) to ($4.33). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Reata Pharmaceuticals.

Reata Pharmaceuticals (NASDAQ:RETA) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($1.14) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.12) by ($0.02). The business had revenue of $7.83 million during the quarter, compared to the consensus estimate of $7.76 million. Reata Pharmaceuticals had a negative return on equity of 3,282.73% and a negative net margin of 410.38%.

Several research analysts have commented on RETA shares. National Securities started coverage on Reata Pharmaceuticals in a research report on Thursday, September 26th. They issued a “buy” rating and a $130.00 price target on the stock. Jefferies Financial Group lifted their price target on Reata Pharmaceuticals from $128.00 to $254.00 and gave the stock a “buy” rating in a research report on Tuesday, October 15th. ValuEngine downgraded Reata Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 11th. Robert W. Baird reaffirmed an “outperform” rating and issued a $162.00 price target (up from $105.00) on shares of Reata Pharmaceuticals in a research report on Tuesday, October 15th. Finally, Zacks Investment Research cut Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 16th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $205.75.

NASDAQ RETA traded up $3.79 during trading on Wednesday, hitting $183.97. The company’s stock had a trading volume of 368,640 shares, compared to its average volume of 284,226. The firm has a 50 day moving average price of $102.79 and a 200 day moving average price of $89.44. The firm has a market cap of $5.42 billion, a P/E ratio of -64.10 and a beta of 2.40. Reata Pharmaceuticals has a 52 week low of $47.50 and a 52 week high of $189.39.

In other news, CEO James Warren Huff sold 63,000 shares of the business’s stock in a transaction that occurred on Friday, September 27th. The stock was sold at an average price of $86.61, for a total transaction of $5,456,430.00. Following the sale, the chief executive officer now directly owns 164,157 shares in the company, valued at $14,217,637.77. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Jason Douglas Wilson sold 4,000 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $72.68, for a total value of $290,720.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 99,000 shares of company stock worth $9,772,150. 34.40% of the stock is currently owned by company insiders.

A number of hedge funds have recently made changes to their positions in the stock. Rhumbline Advisers boosted its stake in Reata Pharmaceuticals by 5.9% in the 3rd quarter. Rhumbline Advisers now owns 31,232 shares of the company’s stock valued at $2,508,000 after buying an additional 1,729 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Reata Pharmaceuticals by 25.1% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,240 shares of the company’s stock valued at $100,000 after buying an additional 249 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in Reata Pharmaceuticals by 853.3% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,430 shares of the company’s stock valued at $115,000 after buying an additional 1,280 shares in the last quarter. Osborn Williams & Donohoe LLC boosted its stake in Reata Pharmaceuticals by 3.1% in the 3rd quarter. Osborn Williams & Donohoe LLC now owns 80,908 shares of the company’s stock valued at $6,496,000 after buying an additional 2,450 shares in the last quarter. Finally, Mackenzie Financial Corp acquired a new stake in Reata Pharmaceuticals in the 2nd quarter valued at $693,000. 58.51% of the stock is currently owned by institutional investors and hedge funds.

About Reata Pharmaceuticals

Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases.

See Also: What is meant by a buy rating?

Get a free copy of the Zacks research report on Reata Pharmaceuticals (RETA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Pan American Silver Corp.  to Issue $0.04 Quarterly Dividend
Pan American Silver Corp. to Issue $0.04 Quarterly Dividend
istar Inc  to Issue $0.10 Quarterly Dividend
istar Inc to Issue $0.10 Quarterly Dividend
General Moly  Receives “Buy” Rating from HC Wainwright
General Moly Receives “Buy” Rating from HC Wainwright
Cominar REIT  Rating Reiterated by Echelon Wealth Partners
Cominar REIT Rating Reiterated by Echelon Wealth Partners
Hardwoods Distribution  PT Raised to C$17.00 at CIBC
Hardwoods Distribution PT Raised to C$17.00 at CIBC
Raymond James Analysts Give Cardinal Energy  a C$2.50 Price Target
Raymond James Analysts Give Cardinal Energy a C$2.50 Price Target


 
© 2006-2019 Zolmax.